Literature DB >> 22456617

Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease.

Miki Fujimura1, Takashi Inoue, Hiroaki Shimizu, Atsushi Saito, Shunji Mugikura, Teiji Tominaga.   

Abstract

BACKGROUND: Cerebral hyperperfusion is a potential complication of superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis for moyamoya disease, but the optimal postoperative management has not been determined. Aggressive blood pressure lowering is controversial because of the risk of ischemic complications.
OBJECTIVE: To establish the optimal postoperative management protocol to prevent symptomatic cerebral hyperperfusion in moyamoya disease.
METHODS: N-isopropyl-p-[(123)I]-iodoamphetamine single-photon emission computed tomography was performed 1 and 7 days after STA-MCA anastomosis on 152 hemispheres from 108 consecutive patients with moyamoya disease (2-69, mean 33.3 years). Between 2004 and 2007 (period 1), 65 patients were maintained under normotensive conditions after 93 operations, and only patients with cerebral hyperperfusion underwent blood pressure lowering. Between 2008 and 2010 (period 2), all 43 patients were prospectively subjected to intensive blood pressure lowering (<130 mm Hg of systolic blood pressure) immediately after 59 operations. Then the incidence of symptomatic cerebral hyperperfusion was compared between the two groups.
RESULTS: Systolic blood pressure the day after surgery was significantly lower in period 2 (mean, 120.9 mm Hg) than in period 1 (133.9 mm Hg) (p < 0.0001). Symptomatic cerebral hyperperfusion was seen in 22 patients during period 1 (23 hemispheres, 24.7%), but only in 4 patients during period 2 (6.7%, p = 0.0047). Multivariate analysis revealed that prophylactic blood pressure lowering was significantly associated with the prevention of symptomatic cerebral hyperperfusion (p = 0.015). Symptomatic cerebral hyperperfusion was relieved in all patients without developing a permanent neurological deficit due to cerebral hyperperfusion.
CONCLUSION: Prophylactic blood pressure lowering prevents symptomatic cerebral hyperperfusion after STA-MCA anastomosis in patients with moyamoya disease. Accurate diagnosis of cerebral hyperperfusion and blood pressure lowering, and considering the severity of hemodynamic compromise in the contralateral and/or remote areas are essential for postoperative management of moyamoya disease.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456617     DOI: 10.1159/000336765

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  26 in total

1.  Crossed cerebellar diaschisis as an indicator of severe cerebral hyperperfusion after direct bypass for moyamoya disease.

Authors:  Haruto Uchino; Ken Kazumata; Masaki Ito; Naoki Nakayama; Satoshi Kuroda; Kiyohiro Houkin
Journal:  Neurosurg Rev       Date:  2020-02-19       Impact factor: 3.042

2.  Predictive factors for acute thrombogenesis occurring immediately after bypass procedure for moyamoya disease.

Authors:  Takeshi Mikami; Hime Suzuki; Ryo Ukai; Katsuya Komatsu; Yukinori Akiyama; Masahiko Wanibuchi; Kiyohiro Houkin; Nobuhiro Mikuni
Journal:  Neurosurg Rev       Date:  2019-02-14       Impact factor: 3.042

3.  Assessment of the cortical artery using computed tomography angiography for bypass surgery in moyamoya disease.

Authors:  Hime Suzuki; Takeshi Mikami; Katsuya Komatsu; Shouhei Noshiro; Kei Miyata; Toru Hirano; Masahiko Wanibuchi; Nobuhiro Mikuni
Journal:  Neurosurg Rev       Date:  2016-07-30       Impact factor: 3.042

4.  High variance of intraoperative blood pressure predicts early cerebral infarction after revascularization surgery in patients with Moyamoya disease.

Authors:  Jiaxi Li; Yahui Zhao; Meng Zhao; Penghui Cao; Xingju Liu; Hao Ren; Dong Zhang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2019-06-15       Impact factor: 3.042

5.  Blood-brain barrier permeability change and regulation mechanism after subarachnoid hemorrhage.

Authors:  Zhiqing Li; Guobiao Liang; Teng Ma; Jingchen Li; Ping Wang; Libo Liu; Bo Yu; Yunhui Liu; Yixue Xue
Journal:  Metab Brain Dis       Date:  2014-10-01       Impact factor: 3.584

6.  Uneven cerebral hemodynamic change as a cause of neurological deterioration in the acute stage after direct revascularization for moyamoya disease: cerebral hyperperfusion and remote ischemia caused by the 'watershed shift'.

Authors:  Xian-Kun Tu; Miki Fujimura; Sherif Rashad; Shunji Mugikura; Hiroyuki Sakata; Kuniyasu Niizuma; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2017-03-29       Impact factor: 3.042

7.  Cavernous malformations associated with dural arteriovenous shunts in the central nervous system.

Authors:  Sam Yeol Ha; Dong Ik Kim; Byung Moon Kim; Young Sub Kwon; Dong Joon Kim
Journal:  Neuroradiology       Date:  2012-09-23       Impact factor: 2.804

8.  Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management.

Authors:  Sherif Rashad; Miki Fujimura; Kuniyasu Niizuma; Hidenori Endo; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2016-05-16       Impact factor: 3.042

9.  Time-of-Flight MR Angiography for Detection of Cerebral Hyperperfusion Syndrome after Superficial Temporal Artery-Middle Cerebral Artery Anastomosis in Moyamoya Disease.

Authors:  K Sato; M Yamada; H Kuroda; D Yamamoto; Y Asano; Y Inoue; K Fujii; T Kumabe
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-03       Impact factor: 3.825

10.  Pre-operative higher hematocrit and lower total protein levels are independent risk factors for cerebral hyperperfusion syndrome after superficial temporal artery-middle cerebral artery anastomosis with pial synangiosis in adult moyamoya disease patients-case-control study.

Authors:  Masahito Katsuki; Miki Fujimura; Ryosuke Tashiro; Yasutake Tomata; Taketo Nishizawa; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2020-09-24       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.